TRLV logo

Trulieve Cannabis Corp. Stock Price

NYSE:TRLV Community·US$1.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 17 Fair Values set on narratives written by author

TRLV Share Price Performance

US$9.65
1.57 (19.43%)
US$18.18
Fair Value
US$9.65
1.57 (19.43%)
46.9% undervalued intrinsic discount
US$18.18
Fair Value
Price US$9.65
AnalystConsensusTarget US$18.18
AnalystLowTarget US$15.00
AnalystHighTarget US$21.00

TRLV Community Narratives

·
Fair Value US$18.18 46.9% undervalued intrinsic discount

Federal Rescheduling And Medical Expansion Will Support A Stronger Long Term Cannabis Operator

1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value US$15 35.7% undervalued intrinsic discount

Rescheduling Uncertainty And Texas Execution Risks Will Pressure Results Yet Support Long Term Upside

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value US$21 54.0% undervalued intrinsic discount

Rescheduling Tailwinds And Medical Expansion Will Reinforce Long Term Earnings Power

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Trending Discussion

No trending discussion available.

Updated Narratives

TRLV logo

TRLV: Federal Rescheduling And NYSE Listing Will Support Future Upside Potential

Fair Value: US$18.18 46.9% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TRLV logo

Rescheduling Tailwinds And Medical Expansion Will Reinforce Long Term Earnings Power

Fair Value: US$21 54.0% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
TRLV logo

TRLV: Federal Rescheduling And Georgia Expansion Will Drive Future Upside

Fair Value: US$15 35.7% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with adequate balance sheet.

2 Risks
3 Rewards

Trulieve Cannabis Corp. Key Details

US$1.1b

Revenue

US$461.6m

Cost of Revenue

US$677.4m

Gross Profit

US$1.1b

Other Expenses

-US$467.8m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-2.43
59.47%
-41.07%
37.9%
View Full Analysis

About TRLV

Founded
1940
Employees
5000
CEO
Kimberly Rivers
WebsiteView website
www.trulieve.com

Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, oral, topical, concentrates, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One brands. The company operates dispensaries in Florida, Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania. It operates cultivation and processing facilities in Arizona, Colorado, Florida, Georgia, Maryland, Pennsylvania, and West Virginia. The company also offers medical cannabis dispensary in North Miami Beach, Florida. Trulieve Cannabis Corp. was formerly known as Schyan Exploration Inc./Exploration Schyan Inc. and changed its name to Trulieve Cannabis Corp. in September 2018. Trulieve Cannabis Corp. was incorporated in 1940 and is headquartered in Tallahassee, Florida.

Recent TRLV News & Updates

Narrative Update Aug 13

TRLV: Federal Rescheduling And NYSE Listing Will Support Future Upside Potential

Analysts recently trimmed their fair value estimate for Trulieve Cannabis from about $19.42 to roughly $18.18, citing updated assumptions around discount rates, revenue trends, profit margins, and future P/E multiples. These changes align with a new $15 analyst price target and expectations for the company to benefit from U.S. medical cannabis growth following federal rescheduling.
New Narrative Aug 11

Rescheduling Tailwinds And Medical Expansion Will Reinforce Long Term Earnings Power

Catalysts About Trulieve Cannabis Trulieve Cannabis operates a large vertically integrated medical cannabis platform in the U.S., focused on branded products sold through its own retail network and wholesale partners. What are the underlying business or industry changes driving this perspective?

Recent updates

No updates